Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
CytomX Therapeutics $250 million follow-on offering
We advised the representatives of the underwriters on the offering
Novartis $11 billion notes offering
We advised Novartis on the investment-grade debt offering
CRISPR Therapeutics $600 million convertible notes offering
We advised the initial purchasers on the offering
Integer Holdings cooperation agreement with Irenic Capital Management
We are advising Integer on its cooperation agreement with Irenic Capital
Solid Biosciences $240 million private placement
We advised the lead placement agents
Korro Bio $85 million private placement
We advised the placement agents
Abbott Laboratories $20 billion notes offering
We advised the joint book-running managers on the offering
Oculis Holding $100 million at-the-market offering
We advised the sales agent on the offering
MiniMed $560 million IPO
The carve-out IPO of Medtronic’s diabetes unit is the second largest medtech IPO ever
AbbVie $8 billion senior notes offering
We advised the representatives of the underwriters on the offering